Sara Tolaney (@stolaney1) ranks #2 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 107 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: NATALEE, KEYNOTE-B49, PANKU-Breast01. CMS Open Payments lists $177,137 in 2025 general payments.
At a Glance
- 26 posts naming a trial in 2026
- 20 trials discussed by name
- Breast Cancer: US #2, Global #3 · 107 physicians engaged
- Leading physician voice: #1 of 23 physicians on KEYNOTE-B49; #1 of 23 physicians on PANKU-Breast01
- Presented at ASCO 2026, ESMO 2026 in 2026
- CMS Open Payments lists $177,137 in 2025 general payments.
This Month
What Sara Tolaney has posted in the last 30 days. Updated November 10, 2026.
OptiTROP-Breast01 Sac-TMT vs chemo in mTNBC (≥2chemo/≥1 in MBC) OS: 14.7 vs 9.9 mo, HR 0.60, p=0.0004 @OncoAlert #ESMO26 https://t.co/PLdWIbtkyF
SWITCH trial: ADC switching 25% HR+ 75% TNBC ORR: 0-8.3%, PFS 1.4-3.0 mo @OncoAlert #ESMO26 https://t.co/PWb3X6UIxs
BRIDGET trial beautifully presented by @drsarahsam Adding tucatinib to HP after local therapy for isolated intracranial progression improved PFS in HER2+ MBC @OncoAlert #ESMO26 https://t.co/vIduedfDFh
DESTINY-Breast09 CNS Analysis Assessment of pts with BICR-assessed brain mets (treated and asymptomatic or clinically inactive) n=61 Deeper systemic and CNS response, and higher iORR @OncoAlert #ESMO26 https://t.co/lJhfvJgg2R
KEYNOTE B-49: Chemo +/- pembro in PDL1+ (CPS≥1) HR+ MBC 79% CPS 1-9 53% recv'd capecitabine PFS: 6.7 vs 6.0 mo HR 0.74 OS: HR 1.04 PFS CPS≥10 :7.5 vs 4.4 HR 0.59 @OncoAlert @hoperugo #ESMO26 https://t.co/ZyCmtddjJq
TROPION-Breast02 CNS fabulously presented by @RebeccaDSing n=61 with baseline brain mets n=35 on Dato-DXd arm (16 had prior treatment for brain mets) PFS HR 0.37, OS HR 0.55 iORR: 62.5% vs 37.5% @OncoAlert #ESMO26 https://t.co/XHUe50PHDU
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Sara Tolaney
Physicians who reposted Sara Tolaney’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #2 | #3 | 107 | 253 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Sara Tolaney presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASCO 2026 · OralASCENT-03: PFS2 resultsSource: @ElisaAgostinett on X ↗
- ASCO 2026 · Rapid oralASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab in previously untreated PD-L1+ metastatic TNBC
- ESMO 2026 · Rapid oralRetrospective Exploratory Biomarker Analyses From evERA Breast Cancer: A Phase III Trial of Giredestrant + Everolimus in ER+/HER2- Advanced Breast Cancer in the Post-CDK4/6 Inhibitor SettingEVERA trial profile → · Source: @ElisaAgostinett on X ↗
- ESMO 2026 · PosterGedatolisib vs other regimens post-CDK4/6i and endocrine therapy in PIK3CA wild-type HR+/HER2- advanced breast cancerSource: @DFCI_BreastOnc on X ↗
What Colleagues Are Saying About Sara Tolaney
2026 posts by fellow physicians that mention @stolaney1, quoted word for word.
Sacituzumab Govitecan ± Pembro is now @US_FDA ✅ in 1L metastatic TNBC off #ASCENT03/04! We 🗣️ these trials, findings, and AEs w/ @stolaney1 Full 🗣️: ⭐️ https://t.co/uHH1foTNZ3 ⭐️Also on “Oncology Brothers” podcast @OncUpdates #bcsm #OncTwitter https://t.co/7XVV18oCDz
evERA, by @elmayermd, @stolaney1 et al, is now published in NEJM. Giredestrant outperformed SoC ET when combined with everolimus in HR+/HER2- MBC, particularly in ESR1 mutant disease. Looking forward to having this highly active combo available in clinic. https://t.co/tmEFGZGGOw https://t.co/xUx4cGRoPH
Leave it to @chadinabhan to pull together an exceptional group of faculty on Monday night at #ASCO26! Looking fwd to joining @DrRanaMcKay & @PGrivasMDPhD to discuss the latest developments in GU oncology - then, @VKaklamani, @stolaney1, #GregVidalMD & #JoyceOShaughnessyMD talk #breastcancer. Terrific faculty for GI, #lungcancer, #melanoma, & #braintumors as well - @DrSapnaPatel, @VivekSubbiah, @YJanjigianMD, @GIcancerDoc & so many more! Join us!
evERA BC (Exploratory Analysis) #ESMO26 @stolaney1 Giredestrant + everolimus improved PFS vs standard ET + everolimus in HR+/HER2− advanced breast cancer (HR 0.56; ESR1m: HR 0.38). Benefit was generally consistent across ESR1 variants, clonality, and poor-prognosis genomic subgroups.
Today at 4 PM !! @stolaney1 @elmayermd @nlinmd and others join us for a discussion of highlights from ESMO-breast and preview of key ASCO discussions. Program is live, unrehearsed, and free to join but registration required. See link below. https://t.co/I8SzzhsoVH
evERA BC exploratory biomarker analysis @stolaney1 Giredestrant + everolimus showed PFS benefit vs standard ET + everolimus across ctDNA tumour fractions and ESR1 mutation variants, including Y537 and D538, regardless of clonality. Encouraging consistency despite ESR1 heterogeneity; smaller genomic subgroups remain exploratory. #BCSM #ESMO26 @OncoAlert @Larvol
Trials Sara Tolaney Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| NATALEE | 3 | #2 of 46 | Oct 23, 2026 |
| KEYNOTE-B49 | 2 | #1 of 23 | Oct 24, 2026 |
| PANKU-Breast01 | 2 | #1 of 23 | Oct 23, 2026 |
| DESTINYBreast-05 | 2 | #4 of 11 | Oct 23, 2026 |
| lidERA | 2 | #9 of 23 | Oct 23, 2026 |
| SERENA-6 | 2 | #6 of 39 | Jun 2, 2026 |
| OptiTROP-Breast01 | 1 | #1 of 12 | Oct 26, 2026 |
| SWITCH | 1 | #5 of 23 | Oct 26, 2026 |
| BRIDGET | 1 | #4 of 17 | Oct 26, 2026 |
| DESTINYBreast-09 | 1 | #5 of 13 | Oct 26, 2026 |
| TROPION-Breast02 | 1 | #5 of 26 | Oct 24, 2026 |
| DESTINY-Breast11 | 1 | #4 of 11 | Oct 23, 2026 |
| TALENT (TRIO-US B-12) | 1 | #3 of 23 | Oct 23, 2026 |
| HORIZON-Breast06 | 1 | #11 of 15 | Oct 23, 2026 |
| EVERA | 1 | #4 of 30 | Oct 1, 2026 |
| HER2CLIMB-05 | 1 | #2 of 19 | Jun 2, 2026 |
| VIKTORIA-1 | 1 | #4 of 23 | Jun 2, 2026 |
| persevERA | 1 | #3 of 12 | Jun 2, 2026 |
| OPTIMA (UK) | 1 | #12 of 24 | May 30, 2026 |
| INAVO120 | 1 | #4 of 6 | May 8, 2026 |
Sara Tolaney on NATALEE
NATALEE, B-42, and PANKU-Breast01 in context @OncoAlert #bcsm https://t.co/8bVdIPaOA0
NATALEE: OS data Adjuvant ribociclib in ER+ breast cancer 6 yr OS HR 0.809 (delta 2.1%) BCSS: 0.706 (delta 2.6%) 6 yr iDFS HR 0.741 (delta ~5%) DDFS: HR 0.744 @OncoAlert #ESMO26
NATALEE: 3022 pts PAM50 profile (66% lum A, 28% lum B, 3% basal, 3% HER2E) prognostic lum A HR 0.77, lum B 0.71 Higher genomic risk or proliferation scores show a trend for increased ribo benefit Higher CEACAM6 + Lower GATA3 assoc w/ increased ribo benefit @OncoAlert #ASCO26
Sara Tolaney on KEYNOTE-B49
KEYNOTE B-49: Chemo +/- pembro in PDL1+ (CPS≥1) HR+ MBC 79% CPS 1-9 53% recv'd capecitabine PFS: 6.7 vs 6.0 mo HR 0.74 OS: HR 1.04 PFS CPS≥10 :7.5 vs 4.4 HR 0.59 @OncoAlert @hoperugo #ESMO26 https://t.co/ZyCmtddjJq
Please see the simultaneous publication of KEYNOTE B-49 in @Annals_Oncology https://t.co/DWWKc3TIUl @hoperugo https://t.co/V7imGGElh4
Sara Tolaney on PANKU-Breast01
NATALEE, B-42, and PANKU-Breast01 in context @OncoAlert #bcsm https://t.co/8bVdIPaOA0
PANKU-Breast01 HR+ MBC, prior cdk 4/6i, 1-2 prior chemo Iza-bren vs TPC ~70% 1 prior chemo PFS 8.2 vs 4.0 mo, HR 0.41 p<0.0001 ORR 40.5% vs 20.2% DOR 6.9 mo vs 4.2 mo OS immature Most tox: heme tox, primary GCSF was not required @OncoAlert #ESMO26 https://t.co/zdUlK7U21Q
Sara Tolaney on DESTINYBreast-05
DESTINY-Breast05: TDXd for residual HER2+ dz HRQOL maintained with both TDXd + T-DM1 TDXd assoc w/ longer time to deterioration in pain and arm symptoms c/w T-DM1 @OncoAlert #ESMO26 https://t.co/ffHDPkWvh6
DESTINY-Breast05 ILD/radiation pneumonitis ILD higher in pts from Japan and in pts with moderate/renal impairment @OncoAlert #ASCO26 https://t.co/lgW9KGLdqU
Sara Tolaney on lidERA
Lidera PROs: Adjuvant Giredestrant vs SOC ET More pts reported never experiencing joint pain with minimal changes in severity from BL compared with SOC endocrine therapy Hot flashes + fatigue comparable between arms @OncoAlert #ESMO26 https://t.co/AU8X4cy8V8
lidERA results by menopausal status n=4170 ITT: HR 0.70 (3 yr iDFS 92.4 vs 89.6%) Premen: 41% of all pts, iDFS 94vs 91.5% HR 0.65 Postmenop: iDFS 91.3vs 88.3, HR 0.74 1.5% d/c'd gire vs 5% d/c'd AI in premenop pts due to MSK sx @OncoAlert #ASCO26
Sara Tolaney on SERENA-6
SERENA-6: Very robust data with updated PFS, significant PFS2, and impressive ctDNA clearance. @OncoAlert #ASCO26 https://t.co/fgpSnnUpAT
SERENA-6 Timing of ESR1m emergence Median tests: 3 At first test, 10% ESR1m Detection highest in 12-48 months Cumulative detection rate 19.6% #ESMOBreast2026 @OncoAlert #bcsm
Sara Tolaney on OptiTROP-Breast01
OptiTROP-Breast01 Sac-TMT vs chemo in mTNBC (≥2chemo/≥1 in MBC) OS: 14.7 vs 9.9 mo, HR 0.60, p=0.0004 @OncoAlert #ESMO26 https://t.co/PLdWIbtkyF
Sara Tolaney on SWITCH
SWITCH trial: ADC switching 25% HR+ 75% TNBC ORR: 0-8.3%, PFS 1.4-3.0 mo @OncoAlert #ESMO26 https://t.co/PWb3X6UIxs
Sara Tolaney’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Wonderful discussion by @LoiSher @OncoAlert #ESMO26 https://t.co/pWI8A4Cxw5
Very nice discussion by Antonio Llombart @OncoAlert #ESMO26 https://t.co/vSWZSoxytH
GIM3 FATA presented by @PietroDePlacido Upfront AI and switching from tam showed no difference in DFS or OS Exemestane had a slightly worse DFS than anastrozole, no difference in OS @OncoAlert #ESMO26 https://t.co/hge3aYreRS
APEX Breast01 TQB2102 (biapotropic ADC against HER2 with topo1 payload) Rolditamig Deuderuxtecan (TQB2102) vs TPC Chemo in HER2low MBC, no prior chemo (461 HR+, 81 TNBC) PFS HER2low: 16.4 vs 5.5 mo, HR 0.29 ILD 1.1% @OncoAlert #ESMO2026 https://t.co/tTbO5g3ofI
POP-DURVA 2 cycles of durvalumab for preop TNBC (T1N0) n=78 pCR: 1.4% @OncoAlert #ESMO26 https://t.co/k2ygp7vrVV
Industry Payments
CMS Open Payments · 2025 general payments
$177,137 across 114 payments